Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Depression (US)

June 23, 2008
EMRS
Analysis of: Most Doctors Aren’t Using Electronic Health Records (www.nytimes.com)
mY 6 PERSON GROUP HAS INSTALLED AN EXPENSIVE EMR ABOUT 6 MONTHS AGO . WHILE IT HAS BENEFITED US IN MANY WAYS (BETTER RECORD KEEPING FOR EXAMPLE) IT HAS BEEN VERY EXPENSVE TO INSTALL AND IMPLEMENT (HAVING TO HIRE A TECH GUY TO HELP US WT SERVER CRASHES , ETC THAT OCCUR WEEKLY).  IN ADDITION THE...
Analysis of: Most Doctors Aren’t Using Electronic Health Records (www.nytimes.com)
Electronic Health Records (EHR) are like a marriage, but are difficult to implement.  They are expensive, time-consuming and require a paradigm shift from ALL employees of the practice.  Half of all attempts fail; similar to getting married.  They do save costs of transcription and filing/pulling...
Analysis of: Most Doctors Aren’t Using Electronic Health Records (www.nytimes.com)
This article clearly describes the Catch-22 in which most doctors, except for those employed by the large institutions, find themselves.  We cannot afford to practice the "best" medicine, and yet, if we could, we might well make fewer errors and make medical care for our patients more seamless. ...
June 16, 2008
exenatide
Analysis of: After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 (newsroom.lilly.com)
Once a week treatment for diabetes with no weight gain.
June 16, 2008
mab12
Analysis of: Investigational Anti-IgE Antibody Promising as Extracorporeal Allergy Therapy (www.medscape.com)
more prescribing habits of a more potent antibody. It also would be preferred for those patients whose IgE levels are too great fro treatment with Xolair.
Daniel Wynn, MD, Director, Clinical Research
Daniel Wynn, MD, Director, Clinical Research
Consultants In Neurology Ltd.
Analysis of: Extavia® approved in E.U for treatment of multiple sclerosis, first in planned portfolio of therapies from Novartis (www.asia-manufacturing.com)
Extavia, Novartis' brand of  interferon beta 1b, has been approved for the  treatment of multiple sclerosis by the European Union.  With FTY72, Fingolimod, Novartis has the eye on filing NDA by the end of 2009.  While essentially identical to Bayer's Betaferon interferon beta 1b,...
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder (biz.yahoo.com)
Manipulation of the nicotinic receptor is a novel way to treat ADHD which has significant potential to modify the symptoms of this disorder and to enhance learning and memory.  We have had some difficulty with side effects of varenicline which is a nicotinic partial agonist used in smoking cessation...
Analysis of: Metabolic Syndrome Not Useful in Predicting Cardiovascular Risk (www.medpagetoday.com)
There have been great advances made over the past 40 years in cardiovascular risk assessment.  Nevertheless, 600 people die each day of sudden death. The majority of these individuals had conditions that could have been treated and corrected.
Daniel Wynn, MD, Director, Clinical Research
Daniel Wynn, MD, Director, Clinical Research
Consultants In Neurology Ltd.
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder (biz.yahoo.com)
The data on ABT-089 in adults has been released with positive results, whereas the adolescent/childhood trial is on-going for this novel compound for ADHD.  The key difference is the potential to improve learning, not simply regain attention and lessen hyperactivity.
Analysis of: Warning over drug trial’s effects on testing (www.ft.com)
Direct comparisons between potential competing agents often do not exist Initial FDA approval is usually based on comparisons to placebo A new approval does necessarily mean that the new agent is better than existing ones, although this is implied by industry Industry bears all the costs of efficacy...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 Next21 to 30 of 570

Analytics


Generated at 2009-01-07T19:00:58.307